PIP4K2A — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL690941	0.76	11/20
SCHEMBL690942	0.76	11/20
SCHEMBL691297	0.64	10/20
SCHEMBL691298	0.64	10/20
SCHEMBL1673973	0.53	10/20
SCHEMBL1243748	0.52	10/20
SCHEMBL690095	0.72	9/20
SCHEMBL690096	0.72	9/20
SCHEMBL691610	0.58	9/20
SCHEMBL691611	0.58	9/20
SCHEMBL1243662	0.50	9/20
SCHEMBL2203981	0.50	9/20
SCHEMBL2203988	0.50	9/20
SCHEMBL1244782	0.49	9/20
SCHEMBL1243930	0.47	9/20
SCHEMBL1244356	0.46	9/20
SCHEMBL2882464	0.43	8/20
SCHEMBL2882465	0.43	8/20
SCHEMBL1542859	0.37	8/20
SCHEMBL2128486	0.37	8/20

Clinical trials — most relevant to PIP4K2A by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Effect of the Preoperative Oral Carbohydrate Attenuating Immediate Postoperative Insulin Resistance on PI3K Dependent Signaling Pathway	PHASE4	COMPLETED
Myo-inositol for the Management of Poor Ovarian Responders: A Prospective Randomized Controlled Trial	PHASE2/PHASE3	UNKNOWN
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid	PHASE2	COMPLETED
STAR Cape+BKM120 MBC With Brain Met	PHASE2	COMPLETED
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer	PHASE1/PHASE2	RECRUITING
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome	PHASE1/PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Analysis of Tissues From Patients in Trial of Myo-Inositol to Prevent Lung Cancer	PHASE1	COMPLETED
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery	PHASE1	COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors	PHASE1	NOT_YET_RECRUITING
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers	PHASE1	COMPLETED
Nilotinib in Huntington's Disease	PHASE1	UNKNOWN
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
Partial PTEN Deletion in Breast Cancer	nan	UNKNOWN
NGS in Gallbladder Cancer and Response to Treatment	nan	RECRUITING
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Study of the Pathophysiological Mechanisms Involved in Bleeding Events	nan	COMPLETED
Combining Gene Variants to Improve Risk Prediction for Metabolic (Dysfunction)- Associated Fatty Liver Disease and Its Progression to Cirrhosis in Indian Individuals With Type 2 Diabetes	nan	COMPLETED
New Biomarker-based Strategy to Screen and Monitor for Activated Phosphoinositide 3-kinase δ Syndrome	nan	RECRUITING
PIK3CA in HER2+ BC and pCR Trial	nan	UNKNOWN
Clinical Study Evaluating the Effect of Losartan	nan	RECRUITING
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia	nan	RECRUITING
Duality of Lipids: the Athlete's Paradox	nan	COMPLETED
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA	nan	RECRUITING
Can Dormant Perimenopausal Ovarian Follicles Become FSH Responsive?	nan	UNKNOWN
The Study Aims to Investigate the Effects of Oral Inositols on Insulin-resistance in Children With Obesity.	nan	UNKNOWN
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PIP4K2A binder may also engage these)

Protein	Name	Similarity
Q9R0I8	—	1.000	Q9R0I8 →
O70172	—	1.000	O70172 →
Q5F356	—	1.000	Q5F356 →
O13010	—	1.000	O13010 →
Q80XI4	—	1.000	Q80XI4 →
O88377	—	1.000	O88377 →
PIP4K2B	Phosphatidylinositol 5-phosphate 4-kinase type-2 beta	1.000	landscape →
Q5PQ01	—	0.994	Q5PQ01 →
Q5R488	—	0.990	Q5R488 →
Q91XU3	—	0.990	Q91XU3 →
O88370	—	0.988	O88370 →
PIP4K2C	Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma	0.985	landscape →
Q6GL14	—	0.984	Q6GL14 →
Q0P5F7	—	0.983	Q0P5F7 →
Q6IQE1	—	0.983	Q6IQE1 →
Q9R0U1	—	0.958	Q9R0U1 →
MTMR1	Phosphatidylinositol-3-phosphate phosphatase MTMR1	0.957	landscape →
RNGTT	mRNA-capping enzyme	0.957	landscape →
E9Q4Z2	—	0.957	E9Q4Z2 →
PLCB1	1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1	0.957	landscape →
IP6K2	Inositol hexakisphosphate kinase 2	0.956	landscape →
P97789	—	0.956	P97789 →
Q9QW07	—	0.956	Q9QW07 →
Q8BPM2	—	0.956	Q8BPM2 →
Q07722	—	0.955	Q07722 →
A4IID4	—	0.955	A4IID4 →
A7MBL8	—	0.954	A7MBL8 →
MAP4K5	Mitogen-activated protein kinase kinase kinase kinase 5	0.954	landscape →
Q9Z2C4	—	0.954	Q9Z2C4 →
Q6IQ26	—	0.954	Q6IQ26 →